 On Tuesday, Mind Medicine Inc. NASDAQ:MNMD NEO: MMED DE: MMQ reported the completion of its Phase 1 clinical trial of 18-MC, the companys non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The New York-headquartered psychedelic-focused biotech company noted that the trial was completed in December 2021 with topline results expected in early 2022. 